The present invention relates to interleukins (IL 17 and IL12/23) activity inhibiting composition. Further the present invention is related to novel compositions comprising active pharmaceutical ingredient, optionally in combination with other active pharmaceutical ingredients which are capable of treating the skin diseases or disorders and inhibiting the interleukins (IL 17 and IL12/23) activity. The present invention composition Alstonine compound, an emulsifier, an opacifier, a lubricant, a non-ionic surfactant and excipients including demineralized water.
